natgillin/translations-raw huggingface dataset:
5-fluorouracil intravenous
intravenski bolus/infuzija 5
5-fluorouracil intravenous bolus/infusion, each on Days 1 and 2, every 2 weeks
intravenski bolus/infuzija 5- fluorouracila prvog i drugog dana, svaka 2 tjedna
5-fluorouracil intravenous bolus/infusion, each on Days 1 and 2, every 2 weeks
intravenski bolus/infuzija 5-fluorouracila prvog i drugog dana, svaka 2 tjedna
5-fluorouracil IV bolus/infusion, each on days 1 and 2
5-fluorouracil i.v. bolus/infuzija, oboje 1. i 2. dana
5-FU bolus
bolus 5-FU
5-FU bolus should be reduced and the infusion dose reduced by 20%.
Treba smanjiti dozu bolusne injekcije i infuzije 5-FU za 20%.
5-FU infusion
infuzija 5-FU
5-FU/FA 
5-FU/FA +
5-HT3 antagonists
5-HT3 antagonisti
5-HT3 receptor antagonists, such as granisetron, may be associated with arrhythmias or ECG abnormalities.
Antagonisti 5-HT3 receptora, kao što je granisetron, mogu biti povezani s aritmijama ili poremećajima EKG-a.
5-ml oral
usta od 5 ml
5. p-value=0.0166.
5. p-vrijednost = 0,0166.
5.) Calculate the average Radiochemical Purity (RCP) as follows: 6.) Average % RCP = net CPM bottom half x 100 net CPM top half + net CPM bottom half
5.) Prosječnu radiokemijsku čistoću (RCP) izračunajte na sljedeći način: 6.) Prosječni % RCP = neto CPM donje polovice x 100 neto CPM gornje polovice + neto CPM donje polovice
5.0 (3.5, NR)
5,0 (3,5; ND)
5.0 b
5,0 b
5.0 m vs 4.9 m
5,0 m vs 4,9 m
5.0 mg (N=811)
5,0 mg (N=811)
5.0 mg (N=813)
5,0 mg (N=813)
5.0 mg once daily on days 1-28 every 28 days
5,0 mg jednom dnevno od 1. do 28. dana svakih 28 dana
5.0 mg/kg/day of liposomal amphotericin B (14.3 % of patients treated).
Primarna modificirana analiza prema namjeri liječenja (eng., Modified Intention-To-Treat.
5.0 ml containing 2.50 mg fentanyl ensuring the delivery of 40 doses of 50 micrograms
5,0 ml sadrži 2,50 mg fentanila i osigurava unos 40 doza od 50 mikrograma.
5.0 ml containing 5.00 mg fentanyl ensuring the delivery of 40 doses of 100 micrograms
5,0 ml sadrži 5,00 mg fentanila i osigurava unos 40 doza od 100 mikrograma.
5.0 ml twice daily
5,0 ml dva puta dnevno
5.0 ml twice daily
5,0 ml dvaput dnevno
5.0 months (4.4, 5.8)
5,0 mjeseci (4,4; 5,8)
5.1 (3.7, NR)
5,1 (3,7; ND)
5.1 - 10
5,1 do 10
5.1 cm x 10.2 cm sealant matrix in a tray (polyester).
Matriks za tkivno ljepilo dimenzija 5,1 cm x 10,2 cm na plitici (poliester).
5.1 kg to 10 kg
5,1 kg do 10 kg
5.1 mm wide), biconvex, film-coated tablets, with “TAK” and “ALG-6.25” on printed in grey ink on one side.
„ALG-6,25“ otisnutom sivom tintom na jednoj strani.
5.1 Pharmacodynamic properties
Farmakodinamička svojstva
5.1 weeks (95% CI = 4.4 - 10.1 weeks) as assessed by the Investigator and 6.4 weeks (95% CI = 4.4 -
4,4 - 10,1 tjedan) prema procjeni ispitivača odnosno 6,4 tjedna (95% CI: 4,4 - 10,0 tjedana) prema neovisnoj procjeni.
5.1-10.0 × ULN† (Grade 3)
5,1-10,0 × GGN† (stupanj 3)
5.12 ml (Fill: 6.29 ml)
5,12 ml (Punjenje 6,29 ml)
5.2 m vs 5.1 m
5,2 m vs 5,1 m
5.2 Pharmacokine tic prope rties
Farmakokinetička svojstva
5.2 Pharmacokinetic properties
Farmakokinetiĉka svojstva
5.2 Pharmacokinetic properties
Farmakokinetska svojstva
5.2 Preclinical safety data
Neklinički podaci o sigurnosti primjene
5.2. Pharmacokinetic properties
Farmakokinetička svojstva
5.29 mg (aluminium)
5,29 mg (aluminija) DEAE-dekstran
5.29% and 5.22% at baseline and 6.50% and 6.75% at month 6 for the 0.6 and 0.9 mg twice daily dose groups, respectively) relative to pre-diabetic patients (i.e. n=38 overall; 5.77% and 5.71% at baseline and 7.45% and 7.13% at month 6) or diabetic patients (i.e. n=54 overall; 6.50% and 6.42% at baseline and 7.95% and 8.30% at month 6).
5,29% odnosno 5,22% na početku te 6,50% odnosno 6,75% u 6. mjesecu za dozu od 0,6 odnosno 0,9 mg dvaput na dan) u odnosu na bolesnike u pred-dijabetičkom stanju (tj. n=38 ukupno; 5,77% odnosno 5,71% na početku te 7,45% odnosno 7,13% u 6. mjesecu) ili bolesnike sa šećernom bolešću (tj. n=54 ukupno; 6,50% odnosno 6,42% na početku te 7,95% odnosno 8,30% u 6. mjesecu).
5.3 ml containing 2.65 mg fentanyl ensuring the delivery of 40 doses of 50 micrograms
5,3 ml sadrži 2,65 mg fentanila i osigurava unos 40 doza od 50 mikrograma.
5.3 ml containing 5.30 mg fentanyl ensuring the delivery of 40 doses of 100 micrograms
5,3 ml sadrži 5,30 mg fentanila i osigurava unos 40 doza od 100 mikrograma.
5.3 Pre clinical safety data
Neklinički podaci o sigurnosti primjene
5.3 Pre-clinical safety data
Neklinički podaci o sigurnosti primjene
5.3 Preclinical safety data
5.3. Neklinički podaci o sigurnosti primjene
5.3 Preclinical safety data
Nekliniĉki podaci o sigurnosti primjene
5.3 Preclinical safety data
Neklinički podaci o sigurnosti
5.3% vs 1.6%
5,3% vs 1,6
5.3%), low density lipoprotein (LDL) (7.2% vs 6.6%), triglycerides (9.2% vs 5.8%), glucose (3.5% vs
2,6%), ukupnog kolesterola (8,1% prema 5,3%), lipoproteina niske gustoće (LDL) (7,2% prema
5.4 mL
5,4 mL
5.5 l
5,5 L
5.5 lL
5,5 L
5.5 mm, round, biconvex, white to off-white film-coated tablets, debossed with “10” on one side.
5,5 mm, okrugle, bikonveksne, bijele do gotovo bijele filmom obložene tablete, s oznakom “10” na jednoj strani.
5.5  NR
5,5 - ND
5.6 (4.8, NR)
5,6 (4,8; NR)
5.6 m vs 2.8 m
5,6 m vs 2,8 m
5.6 m vs 5.1 m
5,6 m vs 5,1 m
5.66B [3.37; 9.51]
5,66B [3,37; 9,51]
5.7
(N = 283)
5.7
Remisijac
5.7 [3.1 - 7]
[raspon] 5,7 [3,1 – 7]
5.7% (n = 8) (95% CI: 1.9%, 9.5%) (0.7% CR, 5% PR)
5,7% (n = 8) (95% CI: 1,9%; 9,5%) (0,7% CR, 5% PR)
5.8 % of the adenocarcinoma patients entered the study with locally recurrent disease stage as had been evaluated at baseline.
U studiju je ušlo 5,8 % bolesnika s adenokarcinomom s lokalno rekurentnim stadijem bolesti kao što se procijenilo na početku ispitivanja.
5.8% of patients discontinued INCIVO alone due to rash events and 2.6% of patients discontinued INCIVO combination treatment for rash events compared to none of those receiving peginterferon alfa and ribavirin.
Zbog pojave osipa 5,8% bolesnika prekinulo je liječenje INCIVOM, a 2,6% bolesnika prekinulo je kombinirano liječenje INCIVOM, dok prekida zbog pojave osipa nije bilo ubolesnika koji su primali peginterferon alfa i ribavirin.
5.8***
PHS
5.89 for no increase in anti-pegloticase antibodies and 5.77 L with a range of 2.77 – 10.6 for an increase in anti-pegloticase antibodies.
2,62-5,89 u bolesnika bez porasta razine protutijela na peglotikazu i 5,77 l s rasponom 2,77-10,6 u bolesnika s porastom razine protutijela na peglotikazu.
5.9 versus 9.6 months and OS 14.8 versus 19.9 months), in addition to which excessive rates of diarrhoea were reported in patients receiving the XELIRI regimen (41% XELIRI, 5.1% FOLFIRI).
19,9 mjeseci), a uz to su prijavljene znatno veće stope proljeva u bolesnika koji su primali XELIRI protokol (41% XELIRI, 5.1% FOLFIRI).
50 % of previous dose (both ALIMTA and cisplatin)
50% prethodne doze (i lijeka ALIMTA i cisplatina)
50 % of previous dose (both Pemetrexed Accord and cisplatin)
50% prethodne doze (i lijeka Pemetrexed Accord i cisplatina)
50 % of previous dose (both pemetrexed and cisplatin)
50% prethodne doze (i pemetrekseda i cisplatina)
50 % of previous dose (both pemetrexed and cisplatin)
50% prethodne doze (pemetrekseda i cisplatina)
50 % of previous dose (both Pemetrexed Lilly and cisplatin)
50% prethodne doze (i lijeka Pemetrexed Lilly i cisplatina)
50 % Responder rate
Stopa bolesnika s odgovorom od 50
50 (41, 58)
OBT (N=237)
50 (41, 58)
Placebo +
50 + 50 vials
50 + 50 bočica
50 dose 100 ml vial
50 doza bočica 100 ml.
50 doses
50 doza:
50 doses
50 doze
50 doses (0.5 ml)
50 doza (0,5 ml)
50 doses (100 ml).
50 doza (100 ml)
50 doses.
50 doza
50 film-coated tablets.
50 filmom obloženih tableta.
50 g valnemulin base per 100 g
50 g baze valnemulina po 100 g
50 hard capsules
50 tvrdih kapsula
50 IU (100 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
50 IU (100 IU/ml) aktivnosti rekombinantnog folikulostimulirajućeg hormona (FSH).
50 IU/kg once weekly, adjust dose based on individual response or
50 IU/kg jedanput tjedno, uz prilagodbu doze na temelju odgovora pojedinog bolesnika ili
50 IU/kg)
profilaktička
50 IU/ml after reconstitution).
50 IU/ml nakon pripreme).
50 jars containing 75 mg 13C-urea powder for oral solution 100 breath bags for breath samples
50 posudica koje sadrže 75 mg praška 13C-uree za oralnu otopinu 100 vrećica za uzorke izdahnutog zraka
50 mcg/0.3 ml
50 mcg/0,3 ml
50 mg
50 m
50 mg (1tablet Vimpat 50 mg)
50 mg (1tableta Vimpat 50 mg)
50 mg (purity of at least 97% of IgG)
50 mg (pročišćen do najmanje 97% IgG)
50 mg /
pakovanje)
50 mg BIW
50 mg 2 x tj.
50 mg capsule: Size number 2 capsule with a Swedish orange cap (black imprint “ASK001”) and body (black imprint “50mg”).
50 mg kapsula: kapsula veličine broj 2 s tamnonarančastom kapicom (s crnim natpisom "ASK001") i tijelom (s crnim natipsom "50 mg").
50 mg daily in the morning if you have moderate or severe kidney disease or if you are on dialysis.
50 mg na dan, ujutro, ako imate umjerenu ili tešku bolest bubrega ili ako ste na dijalizi.
50 mg daily taken as one dose in the morning if you are taking Galvus with another medicine called a sulphonylurea.
50 mg na dan, što se uzima kao jedna doza ujutro ako uzimate Galvus s drugim lijekom koji se zove sulfonilureja.
50 mg daily taken as one dose in the morning if you are taking Jalra with another medicine called a sulphonylurea.
50 mg na dan, što se uzima kao jedna doza ujutro ako uzimate Jalru s drugim lijekom koji se zove sulfonilureja.
50 mg daily taken as one dose in the morning if you are taking Xiliarx with another medicine called a sulphonylurea.
50 mg na dan, što se uzima kao jedna doza ujutro ako uzimate Xiliarx s drugim lijekom koji se zove sulfonilureja.
50 mg diphenhydramine
50 mg difenhidramina
50 mg dose — 2 sachets
Doza od 50 mg — 2 vrećice
50 mg film-coated tablets
50 mg filmom obložene tablete
50 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide red (E172).
50 mg filmom obložene tablete: poli(vinilni) alkohol, titanijev dioksid (E171), makrogol 3350, talk, žuti željezov oksid (E172), crveni željezov oksid (E172)
50 mg granules taken orally every 12 hours with fat containing food
50 mg granule, uzimaju se peroralno svakih 12 sati s hranom koja sadrži masti
50 mg hard capsules
Tvrde kapsule od 50 mg
50 mg once daily
50 mg jednom dnevno
50 mg once daily +
50 mg jedanput dnevno +
50 mg once daily +
50 mg jedanput dnevno + 600/100 mg dva puta
50 mg once daily +
Dolutegravir +
50 mg Outer Carton
Synagis 50 mg vanjska kutija
50 mg Pirlimycin
50 mg pirlimicina
50 mg q12h
50 mg svakih 12 sati
50 mg single dose
jedna doza od 50 mg
50 mg solution for injection in pre-filled syringe
50 mg otopina za injekciju u napunjenoj štrcaljki
50 mg suspension for injection
50 mg suspenzija za injekciju
50 mg twice daily (N = 93)
100 mg (N=483)
50 mg/day
50 mg/dan
50 mg/day
induktorima
50 mg/mL (5%) glucose solution for injection.
otopinom glukoze za injekciju od 50 mg/ml (5%)
50 mg/mL (5%) glucose solution for injection.
otopinom natrijeva klorida za injekciju od 9 mg/ml (0,9%); ili otopinom glukoze za injekciju od 50 mg/ml (5%)
50 mg: 14 and 28 orodispersible tablets
50 mg: 14 i 28 raspadljivih tableta za usta
50 micrograms / dose
50 mikrograma / doza
50 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 50 mikrograma
50 ml
10 x 50 ml
50 ml
Otapalo: 50 ml
50 ml & 100 ml vial labels (EU/2/96/001/004, EU/2/96/001/005, EU/2/97/001/007 & EU/2/96/001/008 only)
50 ml i 100 ml bočice s etiketom (EU/2/96/001/004 , EU/2/96/001/005, EU/2/97/001/007 &EU/2/96/001/008 samo)
50 ml (25 doses)
50 ml (25 doza)
50 ml (25 doses) 100 ml (50 doses)
50 ml (25 doza) 100 ml (50 doza)
50 ml (50 doses)
50 ml (50 doza)
50 ml (50 doses) 100 ml (100 doses)
50 ml (50 doza) 100 ml (100 doza)
50 ml bottle
50 ml u bočici
50 ml PET vials, clear 100 ml PET vials, clear
100 ml PET bočice, prozirne.
50 ml PET vials: 2 years.
50 ml plastične PET boce: 2 godine.
50 ml polypropylene syringes
polipropilenskim štrcaljkama od 50 ml
50 ml type I glass vial with a grey butyl rubber stopper, aluminium seal and plastic flip-off cap, containing 4 mg of mifamurtide.
Staklena bočica (staklo tipa I) od 50 ml sa sivim čepom od butilne gume, aluminijskim zatvaračem i plastičnom „flip-off“ kapicom koja sadrži 4 mg mifamurtida.
50 ml vial
bočica 50 ml
50 ml vials, glass type II 100 ml vials, glass type II
50 ml bočice, staklo tip II, 100 ml bočice, staklo tip II.
50 mL white HDPE bottle containing 60 capsules with one 2-in-1 desiccant cylinder and one oxygen absorber cylinder, with a child resistant polypropylene closure
Bijela boca od polietilena visoke gustoće (HDPE)volumena 50 mL koja sadrži 60 kapsula s jednim 2u1 cilindričnim spremnikom sa sredstvom za sušenje i jednim cilindričnim spremnikom za apsorpciju kisika, sa zatvaračem od polipropilena sigurnim za djecu.
50 ml, 100 ml or 200 ml solution in a vial (type II glass) with stopper (chloro-butyl-rubber).
50 ml, 100 ml ili 200 ml otopina u staklenoj bočici (staklo tip II) s gumenim čepom (klorobutil guma).
50 mL/hour
50 ml/h
50 mL/hour every hour
50 ml/h svakih sat vremena
50 mm (2 inch) 21 gauge
50 mm i 21 gaugea
50 modified-release tablets
50 tableta s prilagođenim oslobađanjem
50 multidose containers (200 doses)
spremnika (200 doza)
50 or 300 tablets.
50 ili 300 tableta.
50 pre-filled syringe with 2 separate needles
50 napunjenih štrcaljki s 2 zasebne igle
50 pre-filled syringes without needle
50 napunjenih štrcaljki bez igle
50 PRE-FILLED SYRINGES WITHOUT NEEDLES
50 NAPUNJENIH ŠTRCALJKI BEZ IGALA
50 sachets
50 vrećica
50 syringes
50 štrcaljki
50 SYRINGES WITHOUT NEEDLE
50 ŠTRCALJKI BEZ IGLE
50 tablets
10 tableta
50 tablets
100 tableta
50 tablets
50 filmom obložene tablete
50 tablets
50 tabletta
50 tablets (5 blister strips with 10 tablets each)
50 tableta (5 blister traka s 10 tableta)
50 tablets (5 blister strips with 10 tablets each) Profender 50 mg/10 mg tablets for medium dogs
50 tableta (5 blister traka s 10 tableta) Profender 50 mg/10 mg za srednje velike pse
50 to 60 kg
50 do 60 kg
50 to 75 mg / day*
50 do 75 mg na dan
50 to <100 cells/mm3
50 do <100 stanica
50 to <200
50 do < 200
50 vials
50 bočica
50 vials + 50
50 bočica + 50
50 vials and 50 pre-filled syringes
50 bočica i 50 napunjenih štrcaljki
50 vials and 50 pre-filled syringes + 100 needles
50 bočica i 50 napunjenih štrcaljki + 100 igala
50 VIALS AND 50 PRE-FILLED SYRINGES WITH 100 NEEDLES
50 BOČICA I 50 NAPUNJENIH ŠTRCALJKI SA 100 IGALA
50 VIALS AND 50 PRE-FILLED SYRINGES WITHOUT NEEDLES
50 BOČICA I 50 NAPUNJENIH ŠTRCALJKI BEZ IGALA
50 VIALS AND 50 VIALS
50 BOČICA I 50 BOČICA
50 vials lyophilisate
50 bočica liofilizata
50 vials: suspension (antigen) 50 vials: emulsion (adjuvant)
50 bočica: suspenzija (antigen) 50 bočica: emulzija (adjuvans)
50 vol % ethanol anhydrous (alcohol), i.e. up to 1.58 g ethanol anhydrous per vial, equivalent to 40 ml of beer or 17 ml wine per vial.
50 vol% bezvodnog etanola (alkohol), odnosno do 1,58 g bezvodnog etanola po bočici, što odgovara količini od 40 ml piva ili 17 ml vina po bočici.
50 vol % ethanol anhydrous (alcohol), i.e. up to 3.16 g ethanol anhydrous per vial, equivalent to 80 ml of beer or 33 ml wine per vial.
50 vol% bezvodnog etanola (alkohol), odnosno do 3,16 g bezvodnog etanola po bočici, što odgovara količini od 80 ml piva ili 33 ml vina po bočici.
50 vol % ethanol anhydrous (alcohol), i.e. up to 395 mg ethanol anhydrous per vial, equivalent to 10 ml of beer or 4 ml wine per vial.
50 vol% bezvodnog etanola (alkohol), odnosno do 395 mg bezvodnog etanola po bočici, što odgovara količini od 10 ml piva ili 4 ml vina po bočici.
50 x 1 (Unit dose)
50 x 1 (jedinična doza)
50 x 1 dose (0.5 ml)
50 x 1 doza (0,5 ml)
50 x 1 dose (1.5 ml)
50 x 1 doza (1,5 ml)
50 x 1 hard capsules.
50 x 1 tvrda kapsula.
50 x 1 tablet(unit dose)
50 x 1 tableta
50 x 1 tablets
50 x 1 tableta
50 x 1 tablets (unit
50 x1 tableta (pojedinačna doza)
50 x 1 tablets (unit dose)
50 x 1 tableta (pojedinačna doza)
50 x 1 tablets (unit dose)
50 x1 tableta (pojedinačna doza)
50 x 1 tablets (unit dose)
50x tableta (pojedinačna doza)
50 x 1 tablets (unit dose)
50x1 tableta (pojedinačna doza)
50 x 106 CD54+ cells/250 mL
50 x 106 CD54+ stanica/250 mL
50 x1 ml 2 x 1 ml
50 x1 ml 2 x1 ml
50 µg intranasal 4 times daily) for 7 days
50 µg u nos, 4 puta dnevno) tijekom 7 dana
50 µg/kg
50 - µg/kg
50 – 80 (initial level)
50 – 80 (početna doza)
50 – 90 mg
50-90 mg
50 ≤ and < 80
50 ≤ i < 80
50 g intranasal 4 times daily
50 g intranazalno 4 puta dnevno
50 g intranasal 4 times daily
Flutikazon propionat,
50% (p<0.0001)
50 % (p<0,0001)
50% dose reduction
Smanjenje doze za 50
50% insulin lispro and 50% insulin lispro protamine suspension (rDNA origin)
50% inzulin lispro i 50% suspenzija inzulina lispro s protaminom (dobiveni tehnologijom
50% insulin lispro and 50% insulin lispro protamine suspension (rDNA origin)
50% inzulin lispro i 50% suspenzija inzulina lispro s protaminom (dobiveni tehnologijom rekombinantne DNK)
50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
50% inzulin lispro i 50% suspenzija inzulina lispro s protaminom Za potkožnu primjenu.
50% may be required.
prilagođavati dozu za
50% of previous dose (both ALIMTA and cisplatin)
50% prethodne doze (i lijeka ALIMTA i cisplatina)
50% of previous dose (both pemetrexed and cisplatin)
50% prethodne doze (i pemetrekseda i cisplatina)
50% of previous dose (both Pemetrexed Hospira and cisplatin)
50% prethodne doze (i lijeka Pemetreksed Hospira i cisplatina)
50% Responder rate
Stopa bolesnika s odgovorom od 50
50% responder rates in the 4 mg, 8 mg and 12 mg groups were respectively 23.0%, 31.5%, and 30.0% in combination with enzyme inducing anti-epileptic medicinal products and were 33.3%, 46.5% and 50.0% when perampanel was given in combination with non-enzyme-inducing anti-epileptic medicinal products.
Stope bolesnika s 50%-tnim odgovorom u skupinama koje su primale doze od 4 mg, 8 mg i 12 mg iznosile su 23,0%, 31,5% odnosno 30,0% kad se perampanel davao u kombinaciji s antiepileptičkim lijekovima koji induciraju enzime te 33,3%, 46,5% odnosno 50,0% kad se perampanel davao u kombinaciji s antiepileptičkim lijekovima koji ne induciraju enzime.
50%*** NAd
50%*** NDd
50%; P < .0001
50%; P < 0,0001
50, 50 x 1, 56, 56 x 1, 70, 70 x 1, 98 or 98 x 1 film-coated tablets.
35 x 1, 50, 50 x 1, 56, 56 x 1, 70, 70 x 1, 98 ili 98 x 1 filmom obloženih tableta.
50, 90 or 100 tablets.
14, 15, 20, 21, 30, 50, 90 ili 100 tableta.
50, sector 3, Bucureşti, cod 032266, Romania
50, sector 3, Bukurešt, cod 032266, Rumunjska
50,000 copies/mL
≤ 50 000 kopija/ml
50,000 – Less than 75,000
50 000 – manje od 75 000
50-100 Holmers Farm Way High Wycombe
Holmers Farm Way High Wycombe
50-59 Relative to
50-59 godišnjaci u odnosu na
50-59 Years N=350-384
50-59- godišnjaci N=350-384
50-60 3.5 mg* zoledronic acid
50-60 3,5 mg* zoledronatne kiseline
50.0% (3/6)
Ukupna SVR12 stopaa
50.016 Zaragoza, Spain
50.016 Zaragoza, Španjolska
50.4 micrograms
50,4 mikrograma
50.6% (p<0.0001)
(1,07; 2,15)
50/50/50 micrograms
50/50/50 mikrograma
500 capsules
500 kapsula
500 cells/microlitre or approximately 30% of baseline.
500 stanica po mikrolitru ili približno 30% od početne vrijednosti.
500 cells/mm3
119 stanica/mm3
500 cells/mm3
500 stanica/mm3
500 cells/mm3 (7.5 %)
500 stanica/mm3
500 doses
500 doza
500 doses.
500 doza.
500 hard gastro-resistant capsules (25 cartons of 20 capsules) 100 hard gastro-resistant capsules (5 cartons of 20 capsules)
500 tvrdih želučanootpornih kapsula (25 kutija s 20 kapsula) 100 tvrdih želučanootpornih kapsula (5 kutija s 20 kapsula)
500 International Units/vial simoctocog alfa (200 IU/ml after reconstitution)
500 međunarodnih jedinica simoktokog alfa po bočici (200 IU/ml nakon rekonstitucije)
500 IU
100 IU/ml
500 IU
500 UI
500 IU (octocog alfa) (200 IU/mL after reconstitution).
500 IU (oktokoga alfa) (200 IU/ml nakon pripreme za primjenu).
500 IU human coagulation factor IX (100 IU/ml after reconstitution).
500 IU ljudskog faktora zgrušavanja IX (100 IU/ml nakon pripreme).
500 IU moroctocog alfa for single IV use
500 IU moroktokoga alfa za jednokratnu i.v. primjenu
500 IU octocog alfa
500 IU oktokoga alfa
500 IU octocog alfa (200 IU/ml after reconstitution).
500 IU oktokoga alfa (200 IU/ml nakon pripreme za primjenu).
500 IU* human coagulation factor VIII** (FVIII)
500 IU* ljudskog koagulacijskog faktora VIII** (FVIII)
500 IU* human coagulation factor VIII** (FVIII).
500 IU* ljudskog koagulacijskog faktora VIII** (FVIII)
500 IU/vial
500 IU po bočici
500 mg (two 250 mg capsules) Aptivus together with
500 mg (dvije kapsule od 250 mg) Aptivusa zajedno s
500 mg / 50 mL
500 mg/50 ml
500 mg BID
500 mg 2x/dan
500 mg dexrazoxane
500 mg deksrazoksana
500 mg dose.
500 mg .
500 mg film-coated tablets: indigotine (E132), tartrazine (E102) and iron oxide yellow (E172).
500 mg filmom obložene tablete: indigotin (E132), tartrazin (E102) i žuti željezov oksid (E 172).
500 mg in the morning and 500 mg in the evening
500 mg ujutro i 500 navečer
500 mg Oral QD*
500 mg peroralno QD
500 mg presentation:
Pakovanje od 500 mg:
500 mg single dose
600 mg
500 mg single dose
jedna doza od 500 mg
500 mg tablet: Iron oxide yellow (E172), indigo carmine (E132).
500 mg tableta: žuti željezov oksid (E172), indigo carmine (E132).
500 mg tablet: quinoline yellow aluminium lake (E104)
500 mg tableta: quinoline yellow aluminium lake (E104)
500 mg three times a
Terfenadin
500 mg tipranavir co-administered with low dose ritonavir (200 mg; twice daily) was associated with a 29-fold increase in the geometric mean morning steady-state trough plasma concentrations compared to tipranavir 500 mg twice daily without ritonavir.
500 mg tipranavira s niskom dozom ritonavira (200 mg; dvaput dnevno) daje 29 puta višu geometrijsku srednju vrijednost jutarnje najniže koncentracije tipranavira na kraju doznog intervala u stanju dinamičke ravnoteže nego 500 mg tipranavira dva puta dnevno bez ritonavira.
500 mg Twice Daily
500 mg dvaput dnevno
500 mg/50 mL 1 vial
500 mg/50 ml 1 bočica
500 mg/day
500 mg/dan
500 mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and toxicity profile were comparable to those observed in adult rats.
Profili izloženosti i toksičnosti bili su usporedivim s onim opaženim kod odraslih štakora.
500 mg/kg, no adverse reactions were seen, including upon chronic treatment (500 mg/kg/day administered from 7 to 21 days post partum).
Kod doza od 500 mg/kg, nisu primijećene nikakve nuspojave, uključujući i kronično liječenje (500 mg/kg/dan primijenjeno od 7. do 21. dana nakon poroda).
500 mg: 10, 20, 30, 50, 60, 100 x 1, 100, 120 film-coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets
500 mg: 10, 20, 30, 50, 60, 100 x 1, 100, 120 filmom obloženih tableta i višestruka pakiranja koja sadrže 200 (2 pakiranja od 100) filmom obloženih tableta
500 mg: 10, 20, 30, 50, 60, 100, 120 and multipack of 200 (2 packs of 100) film-coated tablets.
500 mg: 10, 20, 30, 50, 60, 100, 120 i višestruka pakiranja od 200 (2 pakiranja od 100) filmom obloženih tableta.
500 micrograms once every three weeks (6.75 micrograms of Aranesp per kilogram of your body weight), or
500 mikrograma jednom svaka tri tjedna (6,75 mikrograma Aranespa po kilogramu Vaše tjelesne težine), ili
500 micrograms palonosetron administered orally approximately one hour before the start of chemotherapy.
500 mikrograma palonosetrona primijenjenog oralno otprilike jedan sat prije početka kemoterapije.
500 micrograms, maximum plasma palonosetron concentration (Cmax) was 0.81 ± 0.17 ng/ml (mean ± SD) and time to maximum concentration (Tmax) was 5.1 ± 1.7 hours.
500 mikrograma, maksimalna koncentracija palonosetrona u plazmi (Cmax) bila je 0,81 ± 0,17 ng/ml (srednja vrijednost ± SD), a vrijeme do maksimalne koncentracije (tmax) iznosilo je 5,1 ± 1,7 sati.
500 ml diluent
500 ml otapala
500 ml solution in bottles made of Type-I (Ph.Eur.) glass.
500 ml otopine u staklenim bocama tipa I (Ph.Eur.) .
500 ml vials must not be used for pigs and sheep.
Bočice od 500 ml ne smiju se upotrebljavati za svinje i ovce.
500 mL) in daily urine volume were seen that attenuated over several days of dosing.
500 mL) u dnevnom volumenu mokraće umanjena kroz nekoliko dana doziranja.
500 msec in any of the dosing conditions.
500 ms niti kod jednog načina doziranja.